NanoViricides Seeks DRC Approval for Oral Ebola Treatment Trial
NanoViricides applies for DRC approval to start Phase II trial of NV-387 Oral Gummies for Bundibugyo ebolavirus. Oral formulation may improve access in outbreak zones.
This news matters because the Bundibugyo ebolavirus outbreak in the DRC has claimed over 930 lives, and current treatment options are limited. NV-387 Oral Gummies could provide a more accessible, easy-to-administer therapy in resource-constrained regions, potentially saving lives and reducing transmission. If successful, it may also lead to a broad-spectrum antiviral for other filoviruses, enhancing pandemic preparedness globally.
